David S. Followill
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David S. Followill has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Geoffrey S. Ibbott
Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3 shared publications Andrea Molineu
Department of Radiation Physics Radiological Physics Center The University of Texas M. D. Anderson Cancer Center Houston Texas USA
2 shared publicationsDaniela Branco
Department of Radiation Physics The University of Texas MD Anderson Cancer Center Houston TX77054USA
2 shared publicationsGeoffrey S. Ibbott
Department of Radiation Physics Radiological Physics Center The University of Texas M. D. Anderson Cancer Center Houston Texas USA
2 shared publicationsJohn Rong
Department of Imaging Physics The University of Texas MD Anderson Cancer Center Houston TX77054USA
2 shared publicationsPaige Taylor
Department of Radiation Physics The University of Texas MD Anderson Cancer Center Houston TX77054USA
2 shared publications
Latest Publications
- 11 November 2020
- Published by Wiley in Medical Physics
- Vol. 48 (1) , 445-455
Dosimetric impact of commercial CT metal artifact reduction algorithms and a novel in‐house algorithm for proton therapy of head and neck cancer
Purpose Compared the dosimetric impact of all major commercial vendors’ metal artifact reduction (MAR) algorithms to one another, as well as to a novel in‐house technique (AMPP) using an anthropomorphic head phantom. Materials and Methods The phantom was an Alderson phantom, modified to allow for artifact‐filled and baseline (no artifacts) CT scans using teeth capsules made with metal amalgams or bone‐equivalent materials. It also included a cylindrical insert that was accessible from the bottom of the neck and designed to introduce soft tissue features into the phantom that were used in the analysis. The phantom was scanned with the metal teeth in place using each respective vendor’s MAR algorithm: OMAR (Philips), iMAR (Siemens), SEMAR (Canon), and SmartMAR (GE); the AMPP algorithm was designed in‐house. Uncorrected and baseline (bone‐equivalent teeth) image sets were also acquired using a Siemens scanner. Proton spot scanning treatment plans were designed on the baseline image set for five targets in the phantom. Once optimized, the proton beams were copied onto the different artifact‐corrected image sets, with no reoptimization of the beams’ parameters, to evaluate dose distribution differences in the different MAR‐corrected and ‐uncorrected image sets. Dose distribution differences were evaluated by comparing dose volume histogram (DVH) metrics, including planning target volume D95 and clinical target volume D99 coverages, V100, D0.03cc, and heterogeneity indexes, along with a qualitative and water equivalent thickness (WET) analysis. Results Uncorrected CT metal artifacts and commercial MAR algorithms negatively impacted the proton dose distributions of all five target shapes and locations in an inconsistent manner, sometimes overdosing by as much as 11.1% (D0.03) or underdosing by as much as 11.7% (V100) the planning target volumes. The AMPP‐corrected images, however, provided dose distributions that consistently agreed with the baseline dose distribution. The dosimetry results also suggest that the commercial MAR algorithms’ performances varied more with target location and less with target shape. Once relocated further from the metal the target showed dose distributions that agreed more with the baseline for all commercial solutions, improving the overdosing by as much as 6%, implying inadequate HU correction from commercial MAR algorithms. In comparison to the baseline, HU profile shapes were considerably altered by commercial algorithms and reference values showed differences that represent stopping power percentage differences of 2.7% to 10%. The AMPP algorithm plans showed the smallest WET differences with the baseline (0.06cm on average), while the commercial image sets created differences that ranged from 0.11cm to 0.54cm. Conclusions CT metal artifacts negatively impacted proton dose distributions on all five targets analyzed. The commercial MAR solutions performed inconsistently throughout all targets compared to the metal‐free baseline. A lack of CTV coverage and an increased number of hotspots were observed throughout all commercial solutions. Dose distribution errors were related to the proximity to the artifacts, demonstrating the inability of commercial techniques to adequately correct severe artifacts. In contrast, AMPP consistently showed dose distributions that best matched the baseline, likely because it makes use of accurate HU information, as opposed to interpolated data like commercial algorithms.
- 11 November 2020
- Published by Wiley in Medical Physics
- Vol. 48 (1) , 445-455
Dosimetric impact of commercial CT metal artifact reduction algorithms and a novel in‐house algorithm for proton therapy of head and neck cancer
Purpose Compared the dosimetric impact of all major commercial vendors’ metal artifact reduction (MAR) algorithms to one another, as well as to a novel in‐house technique (AMPP) using an anthropomorphic head phantom. Materials and Methods The phantom was an Alderson phantom, modified to allow for artifact‐filled and baseline (no artifacts) CT scans using teeth capsules made with metal amalgams or bone‐equivalent materials. It also included a cylindrical insert that was accessible from the bottom of the neck and designed to introduce soft tissue features into the phantom that were used in the analysis. The phantom was scanned with the metal teeth in place using each respective vendor’s MAR algorithm: OMAR (Philips), iMAR (Siemens), SEMAR (Canon), and SmartMAR (GE); the AMPP algorithm was designed in‐house. Uncorrected and baseline (bone‐equivalent teeth) image sets were also acquired using a Siemens scanner. Proton spot scanning treatment plans were designed on the baseline image set for five targets in the phantom. Once optimized, the proton beams were copied onto the different artifact‐corrected image sets, with no reoptimization of the beams’ parameters, to evaluate dose distribution differences in the different MAR‐corrected and ‐uncorrected image sets. Dose distribution differences were evaluated by comparing dose volume histogram (DVH) metrics, including planning target volume D95 and clinical target volume D99 coverages, V100, D0.03cc, and heterogeneity indexes, along with a qualitative and water equivalent thickness (WET) analysis. Results Uncorrected CT metal artifacts and commercial MAR algorithms negatively impacted the proton dose distributions of all five target shapes and locations in an inconsistent manner, sometimes overdosing by as much as 11.1% (D0.03) or underdosing by as much as 11.7% (V100) the planning target volumes. The AMPP‐corrected images, however, provided dose distributions that consistently agreed with the baseline dose distribution. The dosimetry results also suggest that the commercial MAR algorithms’ performances varied more with target location and less with target shape. Once relocated further from the metal the target showed dose distributions that agreed more with the baseline for all commercial solutions, improving the overdosing by as much as 6%, implying inadequate HU correction from commercial MAR algorithms. In comparison to the baseline, HU profile shapes were considerably altered by commercial algorithms and reference values showed differences that represent stopping power percentage differences of 2.7% to 10%. The AMPP algorithm plans showed the smallest WET differences with the baseline (0.06cm on average), while the commercial image sets created differences that ranged from 0.11cm to 0.54cm. Conclusions CT metal artifacts negatively impacted proton dose distributions on all five targets analyzed. The commercial MAR solutions performed inconsistently throughout all targets compared to the metal‐free baseline. A lack of CTV coverage and an increased number of hotspots were observed throughout all commercial solutions. Dose distribution errors were related to the proximity to the artifacts, demonstrating the inability of commercial techniques to adequately correct severe artifacts. In contrast, AMPP consistently showed dose distributions that best matched the baseline, likely because it makes use of accurate HU information, as opposed to interpolated data like commercial algorithms.
- Open Access
- 24 June 2020
- Published by IntechOpen
Imaging and Neuro-Oncology Clinical Trials of the National Clinical Trials Network (NCTN)
Imaging in neuro-oncology clinical trials can be used to validate patient eligibility, stage at presentation, response to therapy, and radiation therapy. A number of National Clinical Trials Network trials illustrating this are presented. Through the Imaging and Radiation Oncology Core’s quality assurance processes for data acquisition and review, there are uniform data and imaging sets for review. Once the trial endpoints have been analyzed and published, the clinical trial information including pathology, imaging, and radiation therapy objects can be moved to a public archive for use by investigators interested in translational science and the application of new informatics tools for trial analysis.
- 24 June 2020
- Published by IntechOpen
Open AccessImaging and Neuro-Oncology Clinical Trials of the National Clinical Trials Network (NCTN)
Imaging in neuro-oncology clinical trials can be used to validate patient eligibility, stage at presentation, response to therapy, and radiation therapy. A number of National Clinical Trials Network trials illustrating this are presented. Through the Imaging and Radiation Oncology Core’s quality assurance processes for data acquisition and review, there are uniform data and imaging sets for review. Once the trial endpoints have been analyzed and published, the clinical trial information including pathology, imaging, and radiation therapy objects can be moved to a public archive for use by investigators interested in translational science and the application of new informatics tools for trial analysis.
- Open Access
- 7 June 2020
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 21 (8) , 120-130
Development of a stereoscopic CT metal artifact management algorithm using gantry angle tilts for head and neck patients
Dental amalgams are a common source of artifacts in head and neck (HN) images. Commercial artifact reduction techniques have been offered, but are substantially ineffectual at reducing artifacts from dental amalgams, can produce additional artifacts, provide inaccurate HU information, or require extensive computation time, and thus offer limited clinically utility. The goal of this work was to define and validate a novel algorithm and provide a phantom‐based testing as proof of principle. An initial clinical comparison to a vendor's current solution was also performed. The algorithm uses two‐angled CT scans in order to generate a single image set with minimal artifacts posterior to the metal implants. The algorithm was evaluated using a phantom simulating a HN patient with dental fillings. Baseline (no artifacts) geometrical measurements of the phantom were taken in the anterior–posterior, left–right, and superior–inferior directions and compared to the metal‐corrected images using our algorithm to evaluate possible distortion from application of the algorithm. Mean HU numbers were also compared between the baseline scan and corrected image sets. A similar analysis was performed on the vendor's algorithm for comparison. The algorithm developed in this work successfully preserved the image geometry and HU and corrected the CT metal artifacts in the region posterior to the metal. The average total distortion for all gantry angles in the AP, LR, and SI directions was 0.17, 0.12, and 0.14 mm, respectively. The HU measurements showed significant consistency throughout the different reconstructed images when compared to the baseline image sets. The vendor's algorithm also showed no geometrical distortion but performed inferiorly in the HU number analysis compared to our technique. Our novel metal artifact management algorithm, using CT gantry angle tilts, provides a promising technique for clinical management of metal artifacts from dental amalgam.
- 7 June 2020
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 21 (8) , 120-130
Open AccessDevelopment of a stereoscopic CT metal artifact management algorithm using gantry angle tilts for head and neck patients
Dental amalgams are a common source of artifacts in head and neck (HN) images. Commercial artifact reduction techniques have been offered, but are substantially ineffectual at reducing artifacts from dental amalgams, can produce additional artifacts, provide inaccurate HU information, or require extensive computation time, and thus offer limited clinically utility. The goal of this work was to define and validate a novel algorithm and provide a phantom‐based testing as proof of principle. An initial clinical comparison to a vendor's current solution was also performed. The algorithm uses two‐angled CT scans in order to generate a single image set with minimal artifacts posterior to the metal implants. The algorithm was evaluated using a phantom simulating a HN patient with dental fillings. Baseline (no artifacts) geometrical measurements of the phantom were taken in the anterior–posterior, left–right, and superior–inferior directions and compared to the metal‐corrected images using our algorithm to evaluate possible distortion from application of the algorithm. Mean HU numbers were also compared between the baseline scan and corrected image sets. A similar analysis was performed on the vendor's algorithm for comparison. The algorithm developed in this work successfully preserved the image geometry and HU and corrected the CT metal artifacts in the region posterior to the metal. The average total distortion for all gantry angles in the AP, LR, and SI directions was 0.17, 0.12, and 0.14 mm, respectively. The HU measurements showed significant consistency throughout the different reconstructed images when compared to the baseline image sets. The vendor's algorithm also showed no geometrical distortion but performed inferiorly in the HU number analysis compared to our technique. Our novel metal artifact management algorithm, using CT gantry angle tilts, provides a promising technique for clinical management of metal artifacts from dental amalgam.
- Open Access
- 1 May 2017
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 847 (1) , 012029
The IROC Houston Quality Assurance Program: Potential benefits of 3D dosimetry
The IROC Houston QA Center has provided QA core support for NCI clinical trials by ensuring that radiation doses delivered to trial patients are accurate and comparable between participating institutions. Within its QA program, IROC Houston uses anthropomorphic QA phantoms to credential sites. It is these phantoms that have the highest potential to benefit from the use of 3D dosimeters. Credentialing is performed to verify that institutions that are using advanced technologies to deliver complex treatment plans that conform to targets. This makes it increasingly difficult to assure the intended calculated dose is being delivered correctly using current techniques that are 2D-based. A 3D dosimeter such as PRESAGE® is able to provide a complete 3D measured dosimetry dataset with one treatment plan delivery. In our preliminary studies, the 3D dosimeters in our H&N and spine phantoms were found to be appropriate for remote dosimetry for relative dose measurements. To implement 3D dosimetry in IROC Houston's phantoms, the benefit of this significant change to its current infrastructure would have to be assessed and further work would be needed before bringing 3D dosimeters into the phantom dosimetry program.
- 1 May 2017
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 847 (1) , 012029
Open AccessThe IROC Houston Quality Assurance Program: Potential benefits of 3D dosimetry
The IROC Houston QA Center has provided QA core support for NCI clinical trials by ensuring that radiation doses delivered to trial patients are accurate and comparable between participating institutions. Within its QA program, IROC Houston uses anthropomorphic QA phantoms to credential sites. It is these phantoms that have the highest potential to benefit from the use of 3D dosimeters. Credentialing is performed to verify that institutions that are using advanced technologies to deliver complex treatment plans that conform to targets. This makes it increasingly difficult to assure the intended calculated dose is being delivered correctly using current techniques that are 2D-based. A 3D dosimeter such as PRESAGE® is able to provide a complete 3D measured dosimetry dataset with one treatment plan delivery. In our preliminary studies, the 3D dosimeters in our H&N and spine phantoms were found to be appropriate for remote dosimetry for relative dose measurements. To implement 3D dosimetry in IROC Houston's phantoms, the benefit of this significant change to its current infrastructure would have to be assessed and further work would be needed before bringing 3D dosimeters into the phantom dosimetry program.
- Open Access
- 6 March 2014
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 15 (2) , 353-355
Response to Thomsen et al.: Comments on “The Radiological Physics Center's standard dataset for small field size output factors”
- 6 March 2014
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 15 (2) , 353-355
Open AccessResponse to Thomsen et al.: Comments on “The Radiological Physics Center's standard dataset for small field size output factors”
- 26 November 2013
- Published by Springer Nature
- p. 39-51
Anthropomorphic Phantoms for Radiation Oncology Medical Physics
- 26 November 2013
- Published by Springer Nature
- p. 39-51
Anthropomorphic Phantoms for Radiation Oncology Medical Physics
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 3, 311
Quality Assurance for Clinical Trials
Cooperative groups, of which the Radiation Therapy Oncology Group (RTOG) is one example, conduct national clinical trials that often involve the use of radiation therapy. In preparation for such a trial, the cooperative group prepares a protocol to define the goals of the trial, the rationale for its design, and the details of the treatment procedure to be followed. The Radiological Physics Center (RPC) is one of several QA offices that is is charged with assuring that participating institutions deliver doses that are clinically consistent and comparable. The RPC does this by conducting a variety of independent audits and credentialing processes. The RPC has compiled data showing that credentialing can help institutions comply with the requirements of a cooperative group clinical protocol. Phantom irradiations have been demonstrated to exercise an institution’s procedures for planning and delivering advanced external beam techniques (Ibbott et al. 2008, Molineu et al. 2005, Molineu et al. 2013). Similarly, RPC data indicate that a rapid review of patient treatment records or planning procedures can improve compliance with clinical trials (Ibbott et al. 2007). The experiences of the RPC are presented as examples of the contributions that a national clinical trials QA center can make to cooperative group trials. These experiences illustrate the critical need for comprehensive QA to assure that clinical trials are successful and cost-effective. The Radiological Physics Center is supported by grants CA 10953 and CA 81647 from the National Cancer Institute, NIH, DHHS.
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 3, 311
Open AccessQuality Assurance for Clinical Trials
Cooperative groups, of which the Radiation Therapy Oncology Group (RTOG) is one example, conduct national clinical trials that often involve the use of radiation therapy. In preparation for such a trial, the cooperative group prepares a protocol to define the goals of the trial, the rationale for its design, and the details of the treatment procedure to be followed. The Radiological Physics Center (RPC) is one of several QA offices that is is charged with assuring that participating institutions deliver doses that are clinically consistent and comparable. The RPC does this by conducting a variety of independent audits and credentialing processes. The RPC has compiled data showing that credentialing can help institutions comply with the requirements of a cooperative group clinical protocol. Phantom irradiations have been demonstrated to exercise an institution’s procedures for planning and delivering advanced external beam techniques (Ibbott et al. 2008, Molineu et al. 2005, Molineu et al. 2013). Similarly, RPC data indicate that a rapid review of patient treatment records or planning procedures can improve compliance with clinical trials (Ibbott et al. 2007). The experiences of the RPC are presented as examples of the contributions that a national clinical trials QA center can make to cooperative group trials. These experiences illustrate the critical need for comprehensive QA to assure that clinical trials are successful and cost-effective. The Radiological Physics Center is supported by grants CA 10953 and CA 81647 from the National Cancer Institute, NIH, DHHS.
- Open Access
- 8 August 2012
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 13 (5) , 282-289
The Radiological Physics Center's standard dataset for small field size output factors
Delivery of accurate intensity-modulated radiation therapy (IMRT) or stereotactic radiotherapy depends on a multitude of steps in the treatment delivery process. These steps range from imaging of the patient to dose calculation to machine delivery of the treatment plan. Within the treatment planning system's (TPS) dose calculation algorithm, various unique small field dosimetry parameters are essential, such as multileaf collimator modeling and field size dependence of the output. One of the largest challenges in this process is determining accurate small field size output factors. The Radiological Physics Center (RPC), as part of its mission to ensure that institutions deliver comparable and consistent radiation doses to their patients, conducts on-site dosimetry review visits to institutions. As a part of the on-site audit, the RPC measures the small field size output factors as might be used in IMRT treatments, and compares the resulting field size dependent output factors to values calculated by the institution's treatment planning system (TPS). The RPC has gathered multiple small field size output factor datasets for X-ray energies ranging from 6 to 18 MV from Varian, Siemens and Elekta linear accelerators. These datasets were measured at 10 cm depth and ranged from to . The field sizes were defined by the MLC and for the Varian machines the secondary jaws were maintained at a . The RPC measurements were made with a micro-ion chamber whose volume was small enough to gather a full ionization reading even for the field size. The RPC measured output factors are tabulated and are reproducible with standard deviations (SD) ranging from 0.1% to 2.4%, while the institutions' calculated values had a much larger SD range, ranging up to 7.9%. The absolute average percent differences were greater for the than for the other field sizes. The RPC's measured small field output factors provide institutions with a standard dataset against which to compare their TPS calculated values. Any discrepancies noted between the standard dataset and calculated values should be investigated with careful measurements and with attention to the specific beam model. PACS number: 87.53.Bn- 8 August 2012
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 13 (5) , 282-289
Open AccessThe Radiological Physics Center's standard dataset for small field size output factors
Delivery of accurate intensity-modulated radiation therapy (IMRT) or stereotactic radiotherapy depends on a multitude of steps in the treatment delivery process. These steps range from imaging of the patient to dose calculation to machine delivery of the treatment plan. Within the treatment planning system's (TPS) dose calculation algorithm, various unique small field dosimetry parameters are essential, such as multileaf collimator modeling and field size dependence of the output. One of the largest challenges in this process is determining accurate small field size output factors. The Radiological Physics Center (RPC), as part of its mission to ensure that institutions deliver comparable and consistent radiation doses to their patients, conducts on-site dosimetry review visits to institutions. As a part of the on-site audit, the RPC measures the small field size output factors as might be used in IMRT treatments, and compares the resulting field size dependent output factors to values calculated by the institution's treatment planning system (TPS). The RPC has gathered multiple small field size output factor datasets for X-ray energies ranging from 6 to 18 MV from Varian, Siemens and Elekta linear accelerators. These datasets were measured at 10 cm depth and ranged from to . The field sizes were defined by the MLC and for the Varian machines the secondary jaws were maintained at a . The RPC measurements were made with a micro-ion chamber whose volume was small enough to gather a full ionization reading even for the field size. The RPC measured output factors are tabulated and are reproducible with standard deviations (SD) ranging from 0.1% to 2.4%, while the institutions' calculated values had a much larger SD range, ranging up to 7.9%. The absolute average percent differences were greater for the than for the other field sizes. The RPC's measured small field output factors provide institutions with a standard dataset against which to compare their TPS calculated values. Any discrepancies noted between the standard dataset and calculated values should be investigated with careful measurements and with attention to the specific beam model. PACS number: 87.53.Bn - Open Access
- 8 February 2012
- Published by Springer Nature in Radiation Oncology
- Vol. 7 (1) , 19
Assessment of shoulder position variation and its impact on IMRT and VMAT doses for head and neck cancer
Background: For radiotherapy of the head and neck, 5-point mask immobilization is used to stabilize the shoulders. Still, the daily position of the shoulders during treatment may be different from the position in the treatment plan despite correct isocenter setup. The purpose of this study was to determine the interfractional displacement of the shoulders relative to isocenter over the course of treatment and the associated dosimetric effect of this displacement. Methods: The extent of shoulder displacements relative to isocenter was assessed for 10 patients in 5-point thermoplastic masks using image registration and daily CT-on-rails scans. Dosimetric effects on IMRT and VMAT plans were evaluated in Pinnacle based on simulation CTs modified to represent shoulder shifts between 3 and 15 mm in the superior-inferior, anterior-posterior, and right-left directions. The impact of clinically observed shoulder shifts on the low-neck dose distributions was examined. Results: Shoulder motion was 2-5 mm in each direction on average but reached 20 mm. Superior shifts resulted in coverage loss, whereas inferior shifts increased the dose to the brachial plexus. These findings were generally consistent for both IMRT and VMAT plans. Over a course of observed shifts, the dose to 99% of the CTV decreased by up to 101 cGy, and the brachial plexus dose increased by up to 72 cGy. Conclusions: he position of the shoulder affects target coverage and critical structure dose, and may therefore be a concern during the setup of head and neck patients, particularly those with low neck primary disease.
- 8 February 2012
- Published by Springer Nature in Radiation Oncology
- Vol. 7 (1) , 19
Open AccessAssessment of shoulder position variation and its impact on IMRT and VMAT doses for head and neck cancer
Background: For radiotherapy of the head and neck, 5-point mask immobilization is used to stabilize the shoulders. Still, the daily position of the shoulders during treatment may be different from the position in the treatment plan despite correct isocenter setup. The purpose of this study was to determine the interfractional displacement of the shoulders relative to isocenter over the course of treatment and the associated dosimetric effect of this displacement. Methods: The extent of shoulder displacements relative to isocenter was assessed for 10 patients in 5-point thermoplastic masks using image registration and daily CT-on-rails scans. Dosimetric effects on IMRT and VMAT plans were evaluated in Pinnacle based on simulation CTs modified to represent shoulder shifts between 3 and 15 mm in the superior-inferior, anterior-posterior, and right-left directions. The impact of clinically observed shoulder shifts on the low-neck dose distributions was examined. Results: Shoulder motion was 2-5 mm in each direction on average but reached 20 mm. Superior shifts resulted in coverage loss, whereas inferior shifts increased the dose to the brachial plexus. These findings were generally consistent for both IMRT and VMAT plans. Over a course of observed shifts, the dose to 99% of the CTV decreased by up to 101 cGy, and the brachial plexus dose increased by up to 72 cGy. Conclusions: he position of the shoulder affects target coverage and critical structure dose, and may therefore be a concern during the setup of head and neck patients, particularly those with low neck primary disease.
- Open Access
- 1 January 2012
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 2, 34434
Credentialing for participation in clinical trials
The National Cancer Institute (NCI) clinical cooperative groups have been instrumental over the past 50 years in developing clinical trials and evidence-based clinical trial processes for improvements in patient care. The cooperative groups are undergoing a transformation process to launch, conduct, and publish clinical trials more rapidly. Institutional participation in clinical trials can be made more efficient and include the expansion of relationships with international partners. This paper reviews the current processes that are in use in radiation therapy trials and the importance of maintaining effective credentialing strategies to assure the quality of the outcomes of clinical trials. The paper offers strategies to streamline and harmonize credentialing tools and processes moving forward as the NCI undergoes transformative change in the conduct of clinical trials.
- 1 January 2012
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 2, 34434
Open AccessCredentialing for participation in clinical trials
The National Cancer Institute (NCI) clinical cooperative groups have been instrumental over the past 50 years in developing clinical trials and evidence-based clinical trial processes for improvements in patient care. The cooperative groups are undergoing a transformation process to launch, conduct, and publish clinical trials more rapidly. Institutional participation in clinical trials can be made more efficient and include the expansion of relationships with international partners. This paper reviews the current processes that are in use in radiation therapy trials and the importance of maintaining effective credentialing strategies to assure the quality of the outcomes of clinical trials. The paper offers strategies to streamline and harmonize credentialing tools and processes moving forward as the NCI undergoes transformative change in the conduct of clinical trials.